Bladder cancer trial adds chemo, immunotherapy, and radiation after surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This Phase 2 study tests whether adding chemotherapy and immunotherapy along with targeted pelvic radiation after bladder tumor surgery can reduce bladder cancer returning or spreading. It focuses on people with non-metastatic, muscle-invasive urothelial bladder cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your bladder cancer is mainly urothelial type (and not a small-cell type).
- Your cancer stage is T2–T3 with no lymph node or distant spread (N0, M0) based on TURBT and scans.
- You have a recent FDG-PET scan showing no lymph node or metastatic disease within 6 weeks of starting treatment.
- You had a complete TURBT within 8 weeks before starting chemoradiation (or a newer cystoscopy shows no remaining tumor).
- You must be well enough for treatment: good kidney/liver/blood counts and able to do chemo plus pelvic radiation; you also must be expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding two immunotherapy drugs (cemiplimab and fianlimab) to standard chemotherapy (gemcitabine and cisplatin) for people with bladder cancer that has grown into the muscle layer but hasn't spread. The goal is to see if adding these immunotherapies helps shrink the tumor before surgery.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This trial tests whether removing part of the bladder (partial cystectomy) along with standard chemotherapy or immunotherapy before surgery is effective for people with a specific type of bladder cancer that hasn't spread beyond the bladder.
This study tests whether adding immunotherapy drugs (nivolumab alone or nivolumab plus ipilimumab) to standard chemo-radiation can control muscle-invasive bladder cancer while helping people keep their bladder. It aims to find a safer, effective curative treatment for people who want to avoid bladder removal (cystectomy).
This trial tests whether adding the immunotherapy drug pembrolizumab to radiation therapy works as well as or better than the usual chemotherapy given with radiation for a type of bladder cancer that has not invaded the muscle. It is for people whose cancer came back or has high-risk features and who would otherwise need to have their bladder removed.
This trial tests whether combining immunotherapy and low-dose radiation after chemotherapy can help you avoid bladder removal. It's for people whose muscle-invasive bladder cancer has shrunk significantly after initial treatment.
Hear when a new Muscle-Invasive Bladder Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.